Trial Profile
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Daridorexant (Primary)
- Indications Insomnia
- Focus Registrational; Therapeutic Use
- Sponsors Idorsia Pharmaceuticals
- 23 Oct 2023 According to an Idorsia media release, data from this study will be presented at the 2023 World Sleep 2023, a global scientific congress.
- 02 Oct 2023 Results from NCT02783729, NCT02952820, NCT03545191, NCT03575104; determining if there are differences in the number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH) between lemborexant and daridorexant and indirectly comparing lemborexant with daridorexant , published in the Journal of Clinical Psychiatry
- 12 Jul 2023 Results of post-hoc analysis of two studies (NCT02839200 & NCT03545191) assessing the effect of daridorexant on the number, duration, and distribution of night-time wake bouts, and their correlation with daytime functioning, published in the CNS Drugs.